5 integrin up-regulation in brain-derived neurotrophic factor promotes cell motility in human chondrosarcoma
Chih-Yang Lin1#, Hui-Jye Chen1,2#, Te-Mao Li3, Yi-Chin Fong3,4, Shan-Chi Liu5,
Po-Chun Chen6 and Chih-Hsin Tang1,7,8*
1Graduate Institute of Basic Medical Science, China Medical University, Taichung,
Taiwan
2Graduate Institute of Molecular Systems Biomedicine, China Medical University,
Taichung, Taiwan
3School of Chinese Medicine, China Medical University, Taichung, Taiwan 4Department of Orthopaedics, China Medical University Hospital, Taichung, Taiwan
5Institute of Biomedical Sciences, National Chung Hsing University, Taichung,
Taiwan
6Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan 7Department of Pharmacology, School of Medicine, China Medical University,
Taichung, Taiwan
8Department of Biotechnology, College of Health Science, Asia University, Taichung,
Taiwan
#These authors equally contributed to this work.
*Corresponding author Chih-Hsin, Tang PhD
Graduate Institute of Basic Medical Science, China Medical University No. 91, Hsueh-Shih Road, Taichung, Taiwan
Tel: (886) 4-22052121 Ext. 7726. Fax: (886) 4-22333641. E-mail: [email protected] 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Abstract
Chondrosarcoma is a primary malignant bone cancer, with a potent capacity to invade locally and cause distant metastasis; it has a poor prognosis and shows a predilection for metastasis to the lungs. Brain derived neurotrophic factor (BDNF) is a small-molecule protein from the neurotrophin family of growth factors that is associated with the disease status and outcomes of cancers. However, the effect of BDNF on migration activity in human chondrosarcoma cells is mostly unknown. Here, we found that human chondrosarcoma tissues showed significant expression of BDNF, which was higher than that in normal cartilage and primary chondrocytes. We also found that BDNF increased the migration and expression of 5 integrin in human chondrosarcoma cells. In addition, knockdown of BDNF expression markedly inhibited migratory activity. BDNF-mediated migration and 5 integrin up-regulation were attenuated by antibody, inhibitor, or siRNA against the TrkB receptor. Pretreatment of chondrosarcoma cells with PI3K, Akt, and NF-B inhibitors or mutants also abolished BDNF-promoted migration and integrin expression. The PI3K, Akt, and NF-B signaling pathway was activated after BDNF treatment. Taken together, our results indicate that BDNF enhances the migration of chondrosarcoma by increasing 5 integrin expression through a signal transduction pathway that involves the TrkB receptor, PI3K, Akt, and NF-κB. BDNF thus represents a promising new target for treating chondrosarcoma metastasis.
Keywords: BDNF; TrkB; Chondrosarcoma; Metastasis; Integrin. Running title: BDNF induces cancer cell migration
29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54
Introduction
Brain-derived neurotrophic factor (BDNF) is a small basic protein that is highly conserved among different species. In addition, BDNF is widely distributed in various types of tissues . BDNF and its receptor TrkB play key roles in neural development, and some studies have suggested a role for BDNF in cancer cell proliferation, survival, differentiation, and invasiveness . For example, BDNF protects neuroblastoma cells from chemotherapeutic agent induced cytotoxicity .
Chondrosarcomas are a heterogeneous group of neoplasms that share in common the production of cartilage matrix by the tumor cells. It is an uncommon, malignant primary bone tumor with a poor prognosis that may occur at any age between 10 and 80 years. Approximately two-thirds of the affected patients are male , and the tumor usually appears on scapula, sternum, ribs, or pelvis . Clinically, surgical resection remains the primary mode of therapy for chondrosarcoma. Due to the absence of an effective adjuvant therapy, this mesenchymal malignancy has a poor prognosis and, therefore, it is important to explore novel remedies .
Tumor invasion and metastasis are the main biological characteristics of cancer cells . Mortality in cancer patients principally results from metastatic spread of cancer cells to distant organs. Tumor metastasis is a highly complex multistep process, which includes changes in cell-cell adhesion properties . Because integrins expressed on the surface of a cell determine whether the cell can adhere to and survive in a particular microenvironment, the matching of integrins and ligands plays a key role . Integrins are a family of transmembrane glycoprotein adhesion receptors that play central roles in the biology of metazoans by controlling cell adhesion, migration, differentiation, and apoptosis. Integrins form heterodimers of α and β subunits . There are at least 19 α subunits and 8 β subunits that can associate to form 25 unique integrin heterodimers . Integrins play an important role in many extracellular matrix (ECM) matrix proteins such as collagens, fibronectin, laminin, osteopontin, and vitronectin . In addition, integrins have also been implicated in metastasis of lung, breast, bladder, colon cancer, and chondrosarcomas .
Previous studies have shown that BDNF increases cell migration and invasion in human cancer cells . However, the effect of BDNF on integrin expression and migration activity in human chondrosarcoma cells is not well understood. We therefore examined whether BDNF promoted integrin expression and cell motility in human chondrosarcoma cells. Here, we found that BDNF increases migration and up-regulates 5 integrin in human chondrosarcoma cells. Moreover, the TrkB receptor, phosphatidylinositol 3’-kinase (PI3K), Akt, and NF-B signaling pathways were shown to be involved. 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92
Materials and methods Materials
Anti-rabbit and anti-mouse IgG-conjugated horseradish peroxidase, mouse monoclonal antibody specific for 5 integrin was purchased from Chemicon (Temecula, CA). Rabbit polyclonal antibodies specific for BDNF, TrkB, β-actin, p85, p-p85, Akt, p-Akt, p65, p-p65, IKK/, p-IKK/, IB, p-IB, and TrkB, BDNF, and control shRNA plasmids were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). TPCK and pyrrolidine dithiocarbamate (PDTC) were purchased from Calbiochem (San Diego, CA). Recombinant human BDNF was purchased from R&D Systems (Minneapolis, MN, USA). NF-B luciferase plasmid was purchased from Stratagene (La Jolla, CA). The p85 and Akt (Akt K179A) dominant-negative mutants were gifts from Dr. W.M. Fu (National Taiwan University, Taipei, Taiwan). IKK (KM) and IKK (KM) mutants were gifts from Dr. H. Nakano (Juntendo University, Tokyo, Japan). The pSV--galactosidase vector and the luciferase assay kit were purchased from Promega (Madison, MA). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO).
Patients and specimen preparation
The study protocol was approved by the Institutional Review Board of China Medical University Hospital, and all subjects gave informed written consent before enrollment. The specimens of tumor tissue or normal cartilage tissue were obtained from patients who were had been diagnosed with chondrosarcoma or knee osteoarthritis and had undergone surgical resection at China Medical University Hospital. Tissue specimens were ground and then sonicated in protein lysis buffer. Protein levels were analyzed by western blotting.
Immunohistochemistry
Paraffin-embedded tissues were cut into 5-μm-thick sections and mounted on glass slides; these were then rehydrated and incubated in 3% hydrogen peroxide to block endogenous peroxidase activity. Sections were then antigen retrieval was performed using Tris-EDTA (pH 9.0) buffer at 100°C for 3 minutes. The sections were washed and incubated with 0.025% Triton X-100 and 1% BSA in Tris-buffered saline (TBS) for 1 h. The monoclonal mouse anti-human BDNF primary antibody was applied to the slides at a dilution of 1:50 and incubated at 4°C overnight. After 3 washes in PBS, the samples were treated with goat anti-mouse IgG biotin-labeled secondary antibodies at a dilution of 1:50. Bound antibodies were detected with an 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130
ABC kit (Vector Laboratories). The slides were stained with a chromogen diaminobenzidine, washed, counterstained with Delafield's hematoxylin, dehydrated, treated with xylene, and then mounted. The staining intensity was scored from 1 to 5.
Cell culture
The human chondrosarcoma cell line (JJ012) was kindly provided by Dr. Sean P. Scully’s laboratory (University of Miami School of Medicine, Miami, FL, USA) . Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM)/-MEM supplemented with 10% fetal bovine serum (FBS). The human chondrosarcoma cell line (SW1353) was obtained from the American Type Culture Collection. The cells were cultured in DMEM supplemented with 10% FBS. These cells were maintained at 37°C in a humidified atmosphere of 5% CO2.
To establish primary cultures, chondrocytes were isolated from articular cartilage as previously described . The cells were grown in plastic cell culture dishes in 95% air-5% CO2 in DMEM supplied with 20 mM HEPES, 10% heat-inactivated FBS, 2
mM-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin.
Migration assay
Migration activity was measured using a Transwell assay (Costar, NY; pore size, 8-μm) and Transwell membrane was pre-coated with 5 integrin ligand vitronectin (30 l, 1 ug/ml). For the invasion assay, filters were precoated with 30 l Matrigel basement membrane matrix (BD Biosciences, Bedford, MA) for 30 min. The following procedures were conducted in the same manner for both the migration and invasion assays. Before the migration assay was performed, cells were pretreated for 30 min with different concentrations of inhibitors, including the K252a, Ly294002, wortmannin, Akt inhibitor, or vehicle control (0.1% dimethyl sulfoxide). Approximately 1 104 cells were added to the upper chamber in 200 l of serum-free
medium. The lower chamber in 300 l of serum-free medium was applied with BDNF. The plates were incubated for 24 h at 37°C in 5% CO2, and then cells were
fixed in 3.7% formaldehyde solution for 15 min and stained with 0.05% crystal violet in PBS for 15 min. Cells on the upper side of the filters were removed with cotton-tipped swabs, and the filters were washed with PBS. On the other hand, cells on the underside of the filters were examined and counted under a microscope. Each clone was plated in triplicate for each experiment, and each experiment was repeated at least 3 times. The number of migrating cells in each experiment was adjusted according to the results of the cell viability assay to correct for proliferation effects of the BDNF treatment (corrected migrating cell number = counted migrating cell number/percentage of viable cells) .
131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168
Wound-healing migration assay
For the wound-healing migration assay, cells were seeded on 12-well plates at a density of 1 105 cells/well in culture medium. At 24 h after seeding, the monolayer
cells were manually scratched with a pipette blue tip to create extended and definite scratches in the center of the dishes with a bright and clear field (∼2 mm). The detached cells were removed by washing the cells once with PBS. Serum-free medium with or without BDNF was added to each dish. After 24 h migrated, the numbers of migratory cells were counted from the resulting three images for each point and then averaged for each experimental condition. The results were compared with control group after 24 h migrated.
Quantitative real-time polymerase chain reaction
Total RNA was extracted from chondrosarcoma cells using a TRIzol kit (MDBio Inc., Taipei, Taiwan). The reverse transcription reaction was performed using 1 g of total RNA that was reverse transcribed into cDNA using oligo(dT) primers . Quantitative real-time PCR (qPCR) analysis was carried out using Taqman® One-Step RT-PCR Master Mix (Applied Biosystems, CA). Two microliters of cDNA template was added to each 25-μl reaction with sequence-specific primers and Taqman® probes. Sequences for all target gene primers and probes were purchased commercially. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an endogenous control to normalize expression data (Applied Biosystems). qPCR assays were carried out in triplicate on a StepOnePlus sequence detection system. The cycling conditions were as follows: initial 10-min polymerase activation at 95 °C followed by 40 cycles at 95 °C for 15 s and 60 °C for 60 s. To calculate the cycle number at which the transcript was detected (CT), the threshold was set above the non-template control background and within the linear phase of target gene amplification.
Western blot analysis
Cellular lysates were prepared as described previously . Proteins were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to Immobilon polyvinyl difluoride membranes. The blots were blocked with 4% nonfat milk for 1 h at room temperature and then probed with rabbit anti-human antibodies against p85, p-p85, Akt, p-Akt, IKK/, p-IKK/, IB, p-IB, p65, p-p65, BDNF, and TrkB (1:1000) for 1 h at room temperature. After 3 washes, the blots were subsequently incubated with a goat anti-rabbit or goat anti-mouse peroxidase-conjugated secondary antibody (1:1000) for 1 h at room temperature. The blots were 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206
visualized by enhanced chemiluminescence using Kodak X-OMAT LS film (Eastman Kodak, Rochester, NY).
Flow cytometric analysis
Human chondrosarcoma cells were plated in 6-well dishes. The cells were then washed with PBS, detached with trypsin at 37°C, and fixed in 75% ethanol overnight. After being rinsed in PBS, the cells were incubated with mouse anti-human antibody against integrin 5 [(AST-3T, BioLegend); 1:100] for 1 h at room temperature. Subsequently, cells were washed again with PBS and incubated with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse secondary IgG (1:100; Leinco Technologies Inc., St. Louis, MO, USA) for 60 min in the dark. The labeled cells were rinsed in wash buffer, and analyzed by flow cytometry using FACS Calibur and CellQuest software (BD Biosciences).
Transient transfection and reporter gene assay
Human chondrosarcoma cells were plated in 12-well dishes, and cells were grown to 80% confluence. DNA and Lipofectamine 2000 (LF2000; Invitrogen) were premixed for 20 min and then applied to the cells. Twenty-four hours after transfection, the cells were incubated with the indicated agents. Following a further 24 h of incubation, the media wereremoved, and cells were washed once with cold PBS. To prepare lysates, 100 l reporter lysis buffer (Promega, Madison, WI) was added to each well, and cells were scraped from dishes. The supernatant was collected after centrifugation at 13,000 rpm for 5 min. Aliquots of cell lysate (20 l) containing equal amounts of protein (20-30 g) were placed in the wells of an opaque black 96-well microplate. An equal volumeof luciferase substrate was added to all samples, and luminescence was measured using a microplate luminometer. The value for luciferase activity was normalized to transfection efficiency monitored by the co-transfected -galactosidase expressionvector.
Immunofluorocytochemistry
Cells were cultured in 12-mm coverslips. After treatment with BDNF, cells were fixed with 4% paraformaldehyde at room temperature. Thirty minutes later, 0.5% Triton X-100 was added to the cells. The cells were then incubated with rabbit anti-p65 (1:100) and FITC-conjugated goat anti-rabbit secondary antibody (1:100; Leinco Technologies Inc) for 1 h. Finally, cells stained with DAPI for 5 min were washed, mounted, and examined with a Zeiss fluorescence microscope.
Establishment of stably transfected cells 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244
Cells were transfected with BDNF shRNA or control shRNA plasmids with the Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA). After 24 h, cells were trypsinized and replated in DMEM/-MEM supplemented with 10% FBS and maintained at 37°C in a humidified atmosphere of 5% CO2. Subsequently, 10 µg/mL
puromycin (Life Technologies) was used to select stable transfectants. Thereafter, the selection medium was replaced every 3 days. After 2 weeks of selection in puromycin, clones of resistant cells were isolated.
Statistical analysis
Data are presented as mean ± standard error of the mean. Statistical analysis of comparisons between 2 samples was performed using the Student’s t test. Statistical comparisons of more than 2 groups were performed using one-way analysis of variance with Bonferroni’s post-hoc test. In all cases, p < 0.05 was considered significant.
Results
BDNF increases cell motility in human chondrosarcoma cells
BDNF has been reported to be expressed by many types of human cancer cells . However, little is known about the expression of BDNF in human chondrosarcoma cells. We therefore examined the expression of BDNF in human chondrosarcoma patients by using immunohistochemistry and western blotting. We found that protein expression levels of BDNF in chondrosarcoma patients were significantly higher than in primary chondrocytes and normal cartilage (Fig. 1A&B).
It has been reported that BDNF stimulates directional migration and invasion of human cancer cells . We next examined the migratory activity of human chondrosarcoma using the Transwell assay. Stimulation of human chondrosarcoma cells (JJ012 and SW1353 cells) with BDNF increased migratory activity in a dose-dependent manner (Fig. 2A). In addition, the wound-scratching assay demonstrated that BDNF increased wound healing activity in human chondrosarcoma cells (Fig. 2B). Treatment of chondrosarcoma cells with BDNF also increased their ability to invade a Matrigel basement membrane matrix (Fig. 2C). To confirm BDNF- mediated cell migration in human chondrosarcoma cells, cells expressing BDNF-shRNA were established. BDNF expression was reduced by BDNF-shRNA in JJ012/BDNF-shRNA and SW1353/BDNF-JJ012/BDNF-shRNA cells (Fig. 2E). However, knockdown of BDNF expression inhibited the migratory ability of JJ012 and SW1353 cells (Fig. 2D). Therefore, BDNF expression is associated with an invasive and metastatic phenotype in chondrosarcoma cells. 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282
Effect of 5 integrin up-regulation in BDNF-induced motility of chondrosarcoma cells
Previous studies have shown that integrin activation mediates the migration and metastasis of human chondrosarcoma cells . We therefore hypothesized that integrins are involved in BDNF-induced chondrosarcoma cell migration. Incubation of cells with BDNF increased expression of 5 but not v, 2, 5, 1, and 3 integrins (Fig. 3A). We further confirmed that treatment of chondrosarcoma cells with BDNF increased the mRNA and cell surface expression of 5 integrin in a time-dependent manner (Fig. 3B&C). To examine whether 5 integrin is involved in the BDNF-induced increase in cell migration, we transfected cells with siRNA against 5 integrin for 24 h. Western blot analysis showed that protein expression levels of 5 integrin were suppressed (Fig. 3E). In addition, transfection of cells with 5 integrin siRNA significantly abolished BDNF-mediated cell migration (Fig. 3D), suggesting that 5 integrin is crucial to mediating the function of BDNF in tumor cell migration.
BDNF-promoted chondrosarcoma cell migration via the TrkB receptor
It has been reported that BDNF exerts its effects through activation of its specific receptor, TrkB . Therefore, we next determined whether the TrkB receptor is involved in BDNF-mediated cell migration in human chondrosarcoma cells. Pretreatment of cells with the TrkB receptor inhibitor K252a or TrkB receptor monoclonal antibody reduced BDNF-induced increases in cell migration (Fig. 4A&B). In addition, transfection of cells with TrkB shRNA also decreased BDNF-induced cell migration (Fig. 4A&B). Moreover, transfection of cells with TrkB shRNA or pretreatment of cells with the TrkB inhibitor and antibody effectively inhibited BDNF-increased 5 integrin expression of chondrosarcoma cells (Fig. 4C&D). These data suggest that the BDNF/TrkB interaction plays a critical role in integrin expression and migration in chondrosarcoma cells.
PI3K and Akt activation are involved in BDNF-induced cell migration and 5 integrin expression in chondrosarcoma cells
PI3K/Akt is a common downstream molecule of the TrkB receptor . Stimulation of cells with BDNF increased the phosphorylation of p85 (Fig. 5A). Pretreatment of chondrosarcomas with PI3K inhibitors (Ly294002 and wortmannin) abolished BDNF-mediated cell migration and 5 integrin expression (Fig. 5B-D). The PI3K-dependent signaling pathway is known to cause enzymatic activation of Akt Ser473 residue
phosphorylation . To explore the role of PI3K/Akt in cancer migration and integrin expression, we next investigated Akt Ser473 phosphorylation in response to BDNF
283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320
treatment. As shown in Fig. 5A, stimulation of cells with BDNF led to significant induction of Akt Ser473 phosphorylation in a time-dependent manner. However,
pretreatment with an Akt inhibitor greatly reduced BDNF-induced migration and integrin expression in chondrosarcoma cells (Fig. 5B-D). Furthermore, transfection of cells with p85 and Akt mutant also inhibited BDNF-induced migration and 5 integrin expression in chondrosarcoma cells (Fig. 5B-D). In contrast, BDNF-induced p85 and Akt phosphorylation was inhibited upon pretreatment of cells with TrkB antibody, K252a, and Ly294002 (Fig. 5E&F). From these results, it appears that the BDNF/TrkB axis acts through the PI3K/Akt-dependent signaling pathway to enhance 5 integrin expression and cell migration in human chondrosarcoma cells.
NF-B is involved in BDNF-enhanced migration and 5 integrin expression Recent studies have documented that NF-B activation is necessary for the migration and invasion of human chondrosarcomas . To examine whether NF-B activation is involved in the signal transduction pathway leading to migration and integrin expression caused by BDNF, we used the NF-B inhibitor PDTC. PDTC inhibited the enhancement of migration and 5 integrin expression induced by BDNF (Fig. 6A-C). In addition, pretreatment of cells with an IB protease inhibitor TPCK also antagonized the potentiating action of BDNF (Fig. 6A-C). We further examined the upstream molecules involved in BDNF-induced NF-B activation. Transfection with IKKα or IKKβ mutants markedly inhibited BDNF-induced cell migration and 5 integrin expression (Fig. 6A-C). Furthermore, stimulation of chondrosarcoma cells with BDNF promoted IKK/, IB, and p65 phosphorylation in a time-dependent manner (Fig. 6D). Pretreatment of cells with Ly294002, wortmannin, or Akt inhibitor significantly reduced BDNF-induced p65 phosphorylation (Fig. 6E).
To directly assess NF-B activation after BDNF treatment, chondrosarcoma cells were transiently transfected with B-luciferase as an indicator of NF-B activation. BDNF treatment of chondrosarcoma cells for 24 h caused an increase in B-luciferase activity (Fig. 7A). In addition, pretreatment of cells with K252a, Ly294002, wortmannin, Akt inhibitor, PDTC, or TPCK blocked BDNF-enhanced B-luciferase activity (Fig. 7A). Moreover, the BDNF-induced increase in B-luciferase activity was abolished by co-transfection of cells with p85, Akt, IKK, or IKK mutant (Fig. 7B). Pretreatment of cells with Ly294002, wortmannin, or Akt inhibitor also reduced BDNF-induced accumulation of p65 into the nucleus (Fig. 7C). Taken together, these data suggest that activation of the TrkB receptor, PI3K, and Akt are required for BDNF-induced NF-B activation in human chondrosarcoma cells.
321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358
Discussion
Chondrosarcoma is a rare but deadly form of bone cancer and is the second most common type of bone cancer, accounting for nearly 26% of all bone cancers . The metastatic potential of conventional chondrosarcomas correlates well with the histologic tumor grade. Because of the relatively indolent growth rates of many low-and moderate-grade chondrosarcomas, approximately 15% of all metastatic disease-related deaths are more than 5 years after initial diagnosis . Therefore, it is important to develop effective adjuvant therapy to prevent chondrosarcoma metastasis. We hypothesized that BDNF would help direct the metastasis of chondrosarcoma cells. Using western blotting and immunohistochemical analysis, we found that expression of BDNF in human chondrosarcoma tissues was significantly higher than in primary chondrocytes and normal cartilage. Moreover, over-expression of BDNF shRNA inhibited the migratory ability of the cells. Therefore, BDNF expression is associated with a metastatic phenotype in chondrosarcoma cells. Exogenous BDNF also increased migration, wound healing, and invasion in human chondrosarcoma. One of the mechanisms underlying BDNF-directed migration was transcriptional up-regulation of 5 integrin and activation of TrkB receptor, PI3K, Akt, and NF-B signaling pathways.
Integrins link the ECM to intracellular cytoskeletal structures and signaling molecules and are implicated in the regulation of a number of cellular processes, including adhesion, signaling, motility, survival, gene expression, growth, and differentiation . In the present study, BDNF increased mRNA levels of only 5 but no other integrin. We also used 5 integrin siRNA to examine the role of 5 integrin and found that it inhibited BDNF-induced cancer cell migration. The experimental results indicate that BDNF promotes migratory ability through the up-regulation of 5 integrin in human chondrosarcoma cells. In addition to cancer metastasis, a similar signaling pathway has also been reported in breast cancer migration, which involved 5 integrin up-regulation and activation, and mediated the growth and metastasis of murine mammary carcinomas , as well as in osteosarcoma migration, which involved β5 integrin activation . Taken together, these results suggest that β5 integrin activation has an important role in treatment of cancer metastasis.
This key oncogenic signaling pathway has been linked to TrkB receptor activation, including up-regulation of the PI3K/Akt cascade . We demonstrated that PI3K inhibitors and an Akt inhibitor could inhibit BDNF-induced migration and β5 integrin expression, suggesting that PI3K/Akt activation is a requisite event in BDNF-induced motility in these cells. This was confirmed by the observation that p85 and Akt mutants inhibited the enhancement of migration and β5 integrin expression in human chondrosarcoma cells. Incubation of cells with BDNF increased PI3K and Akt 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396
phosphorylation. Pretreatment of cells with K252a and Ly294002 reduced BDNF-mediated Akt phosphorylation. These data suggest that the PI3K-dependent Akt pathway is required for BDNF-induced β5 integrin expression and cancer migration. In contrast to PI3K/Akt signaling, ERK activation has been described a downstream molecule of β5 integrin . We also found that ERK inhibitor PD98059 reduced BDNF-increased cell migration (data not shown). Stimulation of chondrosarcoma cells with BDNF enhanced ERK phosphorylation (data not shown). Therefore, ERK may play a role in BDNF-induced cell motility. Whether PI3K/Akt cross talk with ERK after BDNF simulation is needs further examination.
NF-B has been shown to control the induction of transcription of 5 integrin in human cancer cells . The results of this study show that NF-B activation contributes to BDNF-induced migration and 5 integrin expression in human chondrosarcoma cells and that inhibitors of the NF-B-dependent signaling pathway, including PDTC or TPCK, inhibit BDNF-induced 5 integrin expression and cancer migration. In an inactivated state, NF-B is normally held in the cytoplasm by the inhibitor protein IB. Upon stimulation, such as by tumor necrosis factor-α, IB proteins become phosphorylated by the multi-subunit IKK complex, which targets IB for ubiquitination, and are then degraded by the 26S proteasome. Finally, the free NF-B is translocated to the nucleus, where it activates the responsive gene . In the present study, using transient transfection with B-luciferase as an indicator of NF-B activity, we also found that BDNF induced an increase in NF-B activity. In addition, K252a, Ly294002, wortmannin, Akt inhibitor, PDTC, and TPCK or p85, Akt, IKK and IKK mutants reduced BDNF-increased NF-B promoter activity. These results indicate that BDNF acts through the TrkB, PI3K, Akt, IKK/, and NF-B pathway to induce cell migration and 5 integrin expression in human chondrosarcoma cells.
The rate-limiting step in metastasis, and a critical stage in cancer progression, is the acquisition of motility by a tumor cell. Lung metastasis is the major cause of mortality for patients with chondrosarcoma. Here, we have revealed critical new insights into BDNF function and its role in chondrosarcoma metastasis. BDNF expression is up-regulated in chondrosarcoma patients, and promotes cell migration. Although the mechanisms involved in BDNF-induced metastasis are not yet completely understood, our study results provide evidence that BDNF acts via the TrkB receptor, PI3K, Akt, and NF-κB signaling pathways. Our data demonstrate the importance of BDNF in the metastasis of chondrosarcoma, and suggest the use of BDNF as a novel therapeutic target for the clinical treatment of chondrosarcoma. 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434
Acknowledgments
We thank Dr. W.M. Fu for providing p85 and Akt mutants and Dr. H. Nakano for providing IKK and IKK mutants. This work was supported by grants from the National Science Council of Taiwan (NSC99-2320-B-039-003-MY3; 100-2320-B-039-028-MY3; 101-2314-B-039-002-MY3)
Conflict of Interest statement
All authors have no financial or personal relationships with other people or organizations that could inappropriately influence our work
435 436 437 438 439 440 441 442 443 444
Reference
1. Numakawa T, Suzuki S, Kumamaru E, Adachi N, Richards M, et al. (2010) BDNF function and intracellular signaling in neurons. Histol Histopathol 25: 237-258.
2. Matsuda S, Fujita T, Kajiya M, Takeda K, Shiba H, et al. (2012) Brain-derived neurotrophic factor induces migration of endothelial cells through a TrkB-ERK-integrin alphaVbeta3-FAK cascade. J Cell Physiol 227: 2123-2129. 3. Yamashiro T, Fukunaga T, Yamashita K, Kobashi N, Takano-Yamamoto T (2001)
Gene and protein expression of brain-derived neurotrophic factor and TrkB in bone and cartilage. Bone 28: 404-409.
4. Nosrat CA, Fried K, Lindskog S, Olson L (1997) Cellular expression of neurotrophin mRNAs during tooth development. Cell and tissue research 290: 569-580.
5. Sun CY, Chu ZB, She XM, Zhang L, Chen L, et al. (2012) Brain-derived neurotrophic factor is a potential osteoclast stimulating factor in multiple myeloma. Int J Cancer 130: 827-836.
6. Akil H, Perraud A, Melin C, Jauberteau MO, Mathonnet M (2011) Fine-tuning roles of endogenous brain-derived neurotrophic factor, TrkB and sortilin in colorectal cancer cell survival. PLoS One 6: e25097.
7. Scala S, Wosikowski K, Giannakakou P, Valle P, Biedler JL, et al. (1996) Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Cancer Res 56: 3737-3742.
8. Barnes R, Catto M (1966) Chondrosarcoma of bone. J Bone Joint Surg Br 48: 729-764.
9. Pescador D, Blanco J, Corchado C, Jimenez M, Varela G, et al. (2012) Chondrosarcoma of the scapula secondary to radiodermatitis. Int J Surg Case Rep 3: 134-136.
10. Yuan J, Dutton CM, Scully SP (2005) RNAi mediated MMP-1 silencing inhibits human chondrosarcoma invasion. J Orthop Res 23: 1467-1474.
11. Liu SS, Chen XM, Zheng HX, Shi SL, Li Y (2011) Knockdown of Rab5a expression decreases cancer cell motility and invasion through integrin-mediated signaling pathway. J Biomed Sci 18: 58.
12. Weis SM, Cheresh DA (2011) alphav Integrins in Angiogenesis and Cancer. Cold Spring Harb Perspect Med 1: a006478.
13. Giancotti FG, Tarone G (2003) Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu Rev Cell Dev Biol 19: 173-206. 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481
14. Wang Y, Shenouda S, Baranwal S, Rathinam R, Jain P, et al. (2011) Integrin subunits alpha5 and alpha6 regulate cell cycle by modulating the chk1 and Rb/E2F pathways to affect breast cancer metastasis. Mol Cancer 10: 84. 15. Shattil SJ, Kim C, Ginsberg MH (2010) The final steps of integrin activation: the
end game. Nat Rev Mol Cell Biol 11: 288-300.
16. Wang Z, Bryan J, Franz C, Havlioglu N, Sandell LJ (2010) Type IIB procollagen NH(2)-propeptide induces death of tumor cells via interaction with integrins alpha(V)beta(3) and alpha(V)beta(5). J Biol Chem 285: 20806-20817.
17. Heyder C, Gloria-Maercker E, Hatzmann W, Niggemann B, Zanker KS, et al. (2005) Role of the beta1-integrin subunit in the adhesion, extravasation and migration of T24 human bladder carcinoma cells. Clin Exp Metastasis 22: 99-106.
18. Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, et al. (2005) Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res 65: 4645-4652.
19. Takenaka K, Shibuya M, Takeda Y, Hibino S, Gemma A, et al. (2000) Altered expression and function of beta1 integrins in a highly metastatic human lung adenocarcinoma cell line. Int J Oncol 17: 1187-1194.
20. Tang CH, Keng YT, Liu JF (2012) HMGB-1 induces cell motility and alpha5beta1 integrin expression in human chondrosarcoma cells. Cancer Lett 322: 98-106.
21. Huang YT, Lai PC, Wu CC, Cheng CC, Chiu TH (2010) TrkB antibody elicits cytotoxicity and suppresses migration/invasion of transitional cell carcinoma cells. Int J Oncol 37: 943-949.
22. Sun CY, Hu Y, Huang J, Chu ZB, Zhang L, et al. (2010) Brain-derived neurotrophic factor induces proliferation, migration, and VEGF secretion in human multiple myeloma cells via activation of MEK-ERK and PI3K/AKT signaling. Tumour Biol 31: 121-128.
23. Block JA, Inerot SE, Gitelis S, Kimura JH (1991) Synthesis of chondrocytic keratan sulphate-containing proteoglycans by human chondrosarcoma cells in long-term cell culture. J Bone Joint Surg Am 73: 647-658.
24. Tong KM, Chen CP, Huang KC, Shieh DC, Cheng HC, et al. (2011) Adiponectin increases MMP-3 expression in human chondrocytes through AdipoR1 signaling pathway. J Cell Biochem 112: 1431-1440.
25. Fong YC, Lin CY, Su YC, Chen WC, Tsai FJ, et al. (2012) CCN6 enhances ICAM-1 expression and cell motility in human chondrosarcoma cells. J Cell Physiol 227: 223-232. 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519
26. Tang CH, Hsu CJ, Fong YC (2010) The CCL5/CCR5 axis promotes interleukin-6 production in human synovial fibroblasts. Arthritis and rheumatism 62: 3615-3624.
27. Huang CY, Chen SY, Tsai HC, Hsu HC, Tang CH (2012) Thrombin induces epidermal growth factor receptor transactivation and CCL2 expression in human osteoblasts. Arthritis and rheumatism 64: 3344-3354.
28. Okugawa Y, Tanaka K, Inoue Y, Kawamura M, Kawamoto A, et al. (2012) Brain-derived neurotrophic factor/tropomyosin-related kinase B pathway in gastric cancer. British journal of cancer.
29. Okamura K, Harada T, Wang S, Ijichi K, Furuyama K, et al. (2012) Expression of TrkB and BDNF is associated with poor prognosis in non-small cell lung cancer. Lung cancer 78: 100-106.
30. Lai TH, Fong YC, Fu WM, Yang RS, Tang CH (2009) Stromal cell-derived factor-1 increase alphavbeta3 integrin expression and invasion in human chondrosarcoma cells. J Cell Physiol 218: 334-342.
31. Chen YJ, Wei YY, Chen HT, Fong YC, Hsu CJ, et al. (2009) Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Physiol 221: 98-108.
32. Au CW, Siu MK, Liao X, Wong ES, Ngan HY, et al. (2009) Tyrosine kinase B receptor and BDNF expression in ovarian cancers - Effect on cell migration, angiogenesis and clinical outcome. Cancer Lett 281: 151-161.
33. Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW, et al. (2006) Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells. Cancer Res 66: 4249-4255.
34. Yao RQ, Qi DS, Yu HL, Liu J, Yang LH, et al. (2012) Quercetin attenuates cell apoptosis in focal cerebral ischemia rat brain via activation of BDNF-TrkB-PI3K/Akt signaling pathway. Neurochemical research 37: 2777-2786.
35. Qiao M, Sheng S, Pardee AB (2008) Metastasis and AKT activation. Cell Cycle 7: 2991-2996.
36. Tang CH, Tsai CC (2012) CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-kappaB signaling pathway. Biochemical pharmacology 83: 335-344.
37. Wu MH, Lo JF, Kuo CH, Lin JA, Lin YM, et al. (2012) Endothelin-1 promotes MMP-13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/mTOR pathways. Journal of cellular physiology 227: 3016-3026. 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557
38. Dorfman HD, Czerniak B (1995) Bone cancers. Cancer 75: 203-210.
39. Fong YC, Yang WH, Hsu SF, Hsu HC, Tseng KF, et al. (2007) 2-methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells. J Orthop Res 25: 1106-1114.
40. Bianchi-Smiraglia A, Paesante S, Bakin AV (2012) Integrin beta5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene.
41. Taverna D, Crowley D, Connolly M, Bronson RT, Hynes RO (2005) A direct test of potential roles for beta3 and beta5 integrins in growth and metastasis of murine mammary carcinomas. Cancer research 65: 10324-10329.
42. Huang CY, Lee CY, Chen MY, Tsai HC, Hsu HC, et al. (2011) Nephroblastoma overexpressed gene (NOV) enhances cell motility and COX-2 upregulation of human osteosarcoma involves alphavbeta5 integrin, ILK and AP-1-dependent pathways. Biochemical pharmacology 81: 577-585.
43. Chen PS, Wang MY, Wu SN, Su JL, Hong CC, et al. (2007) CTGF enhances the motility of breast cancer cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway. Journal of Cell Science 120: 2053-2065.
44. Yan YX, Gong YW, Guo Y, Lv Q, Guo C, et al. (2012) Mechanical strain regulates osteoblast proliferation through integrin-mediated ERK activation. PLoS One 7: e35709.
45. Su CM, Lu DY, Hsu CJ, Chen HT, Huang CY, et al. (2009) Glial cell-derived neurotrophic factor increases migration of human chondrosarcoma cells via ERK and NF-kappaB pathways. J Cell Physiol 220: 499-507.
46. Chang MS, Lee WS, Chen BC, Sheu JR, Lin CH (2004) YC-1-induced cyclooxygenase-2 expression is mediated by cGMP-dependent activations of Ras, phosphoinositide-3-OH-kinase, Akt, and nuclear factor-kappaB in human pulmonary epithelial cells. Mol Pharmacol 66: 561-571.
558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586
Figure legends
Fig. 1. BDNF expression in human chondrosarcoma patients. (A) Total proteins were extracted from chondrosarcoma patients (n=8) and primary chondrocytes (n=8), and subjected to western blot analysis for BDNF. (B) Immunohistochemistry of BDNF expression in normal cartilage (n=4) and chondrosarcoma tissue (n=6). Size bar = 20 m. Results are expressed as the mean ±standard error of mean (SEM).
Fig. 2. BDNF increased cell migration in chondrosarcoma cells. (A) Cells were added to the upper chamber, and then allowed to migrate for 24 h toward BDNF (30-100 ng/ml)-containing medium. (n=4) (B) Cells were treated with BDNF for 24 h, and the wound-scratching assay was performed (n=5). (C) Cells were added to the upper chamber, and then allowed to invasive for 24 h toward BDNF (30-100 ng/ml)-containing medium (n=4). (D&E) The protein levels of BDNF and in vitro migratory activity of cells were measured using western blotting and a Transwell assay (n=4). Results are expressed as the mean ± SEM. *, p < 0.05 compared with the control group. #, p < 0.05 compared with the BDNF-treated group.
Fig. 3. BDNF-directed migration activity of human chondrosarcoma cells involves up-regulation of 5 integrin. (A) JJ012 cells were incubated with BDNF (50 ng/ml) for 24 h, and mRNA expression of v, 2, 5, 1, 3, and 5 integrin was examined by qPCR (n=4). (B&C) Cells were incubated with BDNF (50 ng/ml) for the indicated time intervals, and mRNA and cell surface 5 integrin expression were examined by qPCR and flow cytometry (n=5). (D&E) Cells were transfected with 5 siRNA for 24 h and then allowed to migrate for 24 h toward BDNF (50 ng/ml)-containing medium. The in vitro migration and 5 expression was measured with the Transwell assay and western blotting (n=5). Results are expressed as the mean ± SEM. *, p < 0.05 compared with the control. #, p < 0.05 compared with the BDNF-treated group.
Fig. 4. TrkB receptor is involved in BDNF-mediated migration of human chondrosarcoma cells. (A&B) Cells were pretreated with K252a (50 nM) or TrkB monoclonal antibodies (5 g/ml) for 30 min or transfected with TrkB shRNA for 24 h and then allowed to migrate for 24 h toward BDNF (50 ng/ml)-containing medium. The in vitro migration and wound healing activity was measured (n=5). (C&D) Cells were pretreated with K252a (50 nM) or 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624
TrkB mAb (5 g/ml) for 30 min followed by stimulation with BDNF, and mRNA and cell-surface 5 integrin expression was examined using qPCR and flow cytometry (n=4). Results are expressed as the mean ± SEM. *, p < 0.05 compared with the control. #, p < 0.05 compared with the BDNF-treated group.
Fig. 5. PI3K/Akt pathway is involved in BDNF-induced migration and 5 integrin up-regulation in human chondrosarcoma cells. (A) Cells were incubated with BDNF (50 ng/ml) for the indicated time intervals, and p-p85 and p-Akt was examined by western blotting (n=5). (B) Cells were pretreated for 30 min with Ly294002 (10 μM), wortmannin (1 μM), and Akt inhibitor (1 μM), or transfected with dominant negative (DN) mutants of p85 and Akt for 24 h, and then allowed to migrate for 24 h toward BDNF (50 ng/ml)-containing medium. In vitro migration was examined using a Transwell assay (n=4). (C&D) Cells were pretreated for 30 min with Ly294002 (10 μM), wortmannin (1 μM), and Akt inhibitor (1 μM), or transfected with dominant negative (DN) mutants of p85 and Akt for 24 h, followed by stimulation with BDNF. The mRNA and cell-surface 5 integrin expression was examined using qPCR and flow cytometry (n=5). Cells were pretreated with K252a and TrkB mAb (E) or K252a and Ly294002 (F) for 30 min. This treatment was followed by stimulation with BDNF (50 ng/ml) for 15 min, and p85 (E) and Akt (F) phosphorylation were examined (n=4). Results are expressed as the mean ± SEM. *, p < 0.05 compared with the control. #, p < 0.05 compared with the BDNF-treated group.
Fig. 6. BDNF induces cell migration and 5 integrin up-regulation through NF-B. (A) Cells were pretreated for 30 min with PDTC (10 M) and TPCK (3 M) or transfected with dominant negative (DN) mutants of IKK or IKK for 24 h, and then allowed to migrate for 24 h toward BDNF (50 ng/ml)-containing medium. In vitro migration was examined using a Transwell assay (n=5). (B&C) Cells were pretreated for 30 min with PDTC and TPCK or transfected with IKK or IKK mutants for 24 h, followed by stimulation with BDNF. The mRNA and cell-surface 5 integrin expression was examined using qPCR and flow cytometry (n=4). (D) Cells were incubated with BDNF for the indicated time intervals, and p-IKK, p-IB, and p-p65 was examined by western blotting (n=5). (E) Cells were pretreated for 30 min with Ly294002, wortmannin, and Akt inhibitor, followed by stimulation with BDNF, and p-p65 expression was examined by western blotting (n=4). 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662
Results are expressed as the mean ± SEM. *, p < 0.05 compared with the control. #, p < 0.05 compared with the BDNF-treated group.
Fig. 7. TrkB/PI3K/Akt pathway is involved in BDNF-mediated NF-B activation. (A&B) Cells were pretreated with Ly294002, wortmannin, Akt inhibitor, PDTC, and TPCK for 30 min or transfected with mutants of p85, Akt, IKK, and IKK before exposure to BDNF. NF-B luciferase activity was measured, and the results were normalized to -galactosidase activity and expressed as the mean ± SEM. for 3 independent experiments performed in triplicate (n=5). (C) Cells were pretreated with Ly294002, wortmannin, and Akt inhibitor for 30 min then stimulated with BDNF for 60 min, and p65 immunofluorescence staining was examined (n=4). Size bar = 20 m. Results are expressed as the mean ± SEM. *, p < 0.05 compared with the control. #, p < 0.05 compared with the BDNF-treated group.
663 664 665 666 667 668 669 670 671 672 673 674 675 676
